Corcept Therapeutics Inc
- Last sale
- Nov 12, 2026 · -1.01%
- Market cap
- $8.07B
- 109.44M shares
- Filings
- 1,074
Q3 2026+12.8% FY25 yoy
Q3 2026−29.4% FY25 yoy
Q3 2026−67.3% FY25 yoy
Q3 2026derived−27.7% FY25 yoy
Q3 2026−33.3% FY25 yoy
Q3 2026−5.6% FY25 yoy
- $8.07B
- 49.7×
- 8.4×
- 9.7×
- 2.41%
- —
Twelve months to Sep 30, 2026 · derived
Price
Nov 12, 2026 · IEX last sale
IEX last saleClose of recordAs traded
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
Financials
Revenue
| Period | Ended | Value | Kind | Source trail |
|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $761,407,000 | reported | |
| FY 2024 | 2024-12-31 | $675,040,000 | reported | |
| FY 2023 | 2023-12-31 | $482,375,000 | reported | |
| FY 2022 | 2022-12-31 | $401,858,000 | reported | |
| FY 2021 | 2021-12-31 | $365,978,000 | reported | |
| FY 2020 | 2020-12-31 | $353,874,000 | reported | |
| FY 2019 | 2019-12-31 | $306,486,000 | reported | |
| FY 2018 | 2018-12-31 | $251,247,000 | reported | |
| FY 2017 | 2017-12-31 | $159,201,000 | reported | |
| FY 2016 | 2016-12-31 | $81,321,000 | reported | |
| FY 2015 | 2015-12-31 | $50,286,000 | reported | |
| FY 2014 | 2014-12-31 | $26,551,000 | reported |
Capital returns
| Fiscal year | Dividends | Buybacks | Total | Per share | Shares | Shares · yoy | of free cash flow |
|---|---|---|---|---|---|---|---|
| FY2025 | — | $172.92M | $172.92M | — | 106.37M sh | +0.8% | 122.0% |
| FY2024 | — | $15.66M | $15.66M | — | 105.50M sh | +1.9% | 8.0% |
| FY2023 | — | $0.00 | $0.00 | — | 103.52M sh | −4.1% | 0.0% |
| FY2022 | — | $0.00 | $0.00 | — | 107.90M sh | +1.8% | 0.0% |
| FY2020 | — | $9.95M | $9.95M | — | 117.31M sh | +2.4% | 6.6% |
Pharmaceutical preparations
Corcept Therapeutics Inc is the 42nd largest of the 553 covered companies the SEC files under this code, by revenue. SIC 2834
CompanyRevenueGrowthNet marginMarket cap
HRMYHarmony Biosciences Holdings, Inc.$868.5M21.5%18.3%$2.0BTLXTelix Pharmaceuticals Ltd$803.8M55.6%0.9%—COLLCollegium Pharmaceutical, Inc$780.6M23.6%8.1%$776.1M
CORTCorcept Therapeutics Inc (this company)$761.4M12.8%13.1%$8.1B
EBSEmergent BioSolutions Inc.$742.9M28.8%7.1%$302.3MPCRXPacira BioSciences, Inc.$726.4M3.6%1.0%$1.5BAMPHAmphastar Pharmaceuticals, Inc.$719.9M1.7%13.6%$1.2BKNSAKiniksa Pharmaceuticals International, plc$677.6M60.1%8.7%$15.1BRAREUltragenyx Pharmaceutical Inc.$673.0M20.2%85.4%$1.6BPeers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.
Corcept Therapeutics Inc · CIK 1088856 · Engraved from SEC EDGAR